LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Zhu, Andrew X.; Kang, Yoon-Koo; Rosmorduc, Olivier; Evans, T.R. Jeffrey; Santoro, Armando; Ross, Paul; Gane, Edward; Vogel, Arndt; Jeffers, Michael; Meinhardt, Gerold; Peña, Carol E.A. (2016)
Publisher: American Association for Cancer Research
Languages: English
Types: Article
Subjects:

Classified by OpenAIRE into

mesheuropmc: neoplasms
Purpose: Sorafenib is the current standard therapy for advanced HCC, but validated\ud biomarkers predicting clinical outcomes are lacking. This study aimed to identify biomarkers\ud predicting prognosis and/or response to sorafenib, with or without erlotinib, in HCC patients from\ud the phase 3 SEARCH trial.\ud Experimental Design: 720 patients were randomized to receive oral sorafenib 400 mg BID plus\ud erlotinib 150 mg QD or placebo. Fifteen growth factors relevant to the treatment regimen and/or\ud to HCC were measured in baseline plasma samples.\ud Results: Baseline plasma biomarkers were measured in 494 (69%) patients (sorafenib plus\ud erlotinib, n=243; sorafenib plus placebo, n=251). Treatment arm–independent analyses showed\ud that elevated HGF (HR, 1.687 [high vs low expression]; endpoint multiplicity adjusted [e-adj]\ud P=0.0001) and elevated plasma VEGF-A (HR, 1.386; e-adj P=0..0377) were significantly\ud associated with poor OS in multivariate analyses, and low plasma KIT (HR, 0.75 [high vs low];\ud P=0.0233; e-adj P=0.2793) tended to correlate with poorer OS. High plasma VEGF-C\ud independently correlated with longer TTP (HR, 0.633; e-adj P=0.0010) and trended toward\ud associating with improved disease control rate (univariate:OR, 2.047; P=0.030; e-adj P=0.420).\ud In 67% of evaluable patients (339/494), a multimarker signature of HGF, VEGF-A, KIT, epigen,\ud and VEGF-C correlated with improved median OS in multivariate analysis (HR, 0.150;\ud P<0.00001). No biomarker predicted efficacy from erlotinib.\ud Conclusions: Baseline plasma HGF, VEGF-A, KIT, and VEGF-C correlated with clinical\ud outcomes in HCC patients treated with sorafenib with or without erlotinib. These biomarkers\ud plus epigen constituted a multimarker signature for improved OS.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 2D3o9wnloaded from clincancerre2s9.aacrjournals.org on May 26, 28016. © 2016 American Assoc1iation for Cancer Research.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article